Loading...
•
Sep 30, 2022
Pacira Q3 2022 Earnings Report
Pacira BioSciences reported third quarter results with revenue increasing 31% over prior year.
Key Takeaways
Pacira BioSciences reported a strong third quarter with total revenues of $167.5 million, a 31% increase compared to the third quarter of 2021. The company reported a net loss of $0.7 million, or $(0.02) per share, and an adjusted EBITDA of $55.2 million.
Total revenues reached $167.5 million.
EXPAREL net product sales were $132.6 million.
ZILRETTA net product sales were $26.5 million.
iovera° net product sales were $4.5 million.
Revenue by Segment
Forward Guidance
Pacira is reiterating its full-year 2022 operating expense guidance.
Positive Outlook
- Non-GAAP R&D expense of $75 million to $85 million.
- Non-GAAP SG&A expense of $220 million to $230 million.
- Stock-based compensation of $47 million to $50 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...